Before joining THP, Paul was Head of Strategy and Corporate Development for Life Technologies where he was responsible for spearheading the company’s corporate strategy, licensing, business development and acquisition activities. He held the same position at Invitrogen Corporation prior to the merger with Applied Biosystems in 2008. In his tenure at Life Technologies and its legacy companies, Dr. Grossman has led the acquisition or divestment of more than 25 businesses, including the merger of Invitrogen and Applied Biosystems, and was responsible for a corporate development strategy that included novel approaches to grow and monetize the company’s substantial intellectual property portfolio of over 4,000 patents and licenses. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 20 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. Dr. Grossman received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. He has authored numerous scientific publications and holds more than 20 U.S. patents. Paul currently represents THP on the board of Agena Bioscience (acquired by Mesa Laboratories), Argonaut Manufacturing Services, Nimble Therapeutics, Specific Diagnostics, Teknova (NASDAQ:TKNO) and Verogen.
Paul D. Grossman, Ph.D.